RNA治療のインド市場の評価：タイプ別、製品別、適応症別、エンドユーザー別、地域別、機会、予測（2018年度～2032年度）

インドのRNA治療の市場規模は、2024年度の6億2,739万米ドルから2032年度に19億994万米ドルに達すると予測され、2025年度～2032年度の予測期間にCAGRで15.33％の成長が見込まれます。市場の成長を支えているのは、慢性疾患の流行、医療・製薬部門のアップグレードに向けた投資の増加、研究の進行、政府からの支援の増加です。

糖尿病や心血管疾患などのさまざまな慢性疾患の脅威が増大していることが、最先端の治療法の採用を後押しし、インドのRNA治療市場の需要を押し上げています。Indian Heart Association（IHA）の推計によると、インドは世界の心臓病患者の約60％を占めています。RNAは機能的に特異的で生物学的に多様な性質を持つため、機能喪失や機能獲得の目的で使用することができます。遺伝子編集とマイクロRNAに基づく新たな技術は、複雑な疾患の負担を斬新な方法で軽減しています。RNAに基づく遺伝子編集は、複雑な疾患を長期にわたってコントロールし、単発性心血管系疾患の恒久的な治癒をもたらすと予測されています。

バイオリアクターや複雑なセットアップを必要とする生物学的製剤とは異なり、RNA治療薬は化学的に合成することができるため、実行可能なRNA候補が同定された場合、迅速に試験および生産することができます。これらの治療法は再現性が高いため、国内のさまざまな市場参入企業や研究機関は、これまで治療不可能だった疾患に対抗するための適切な治療法を特定するために積極的に投資しています。さらに、RNA治療は多くの患者集団に恩恵を与えることができるため、インドのような人口密度の高い国にとって必要不可欠であり、RNA治療に関する研究活動への注目も高まっています。

当レポートでは、インドのRNA治療市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 インドのRNA治療市場の見通し（2018年度～2032年度）

• 市場規模の分析と予測
  • 金額
  • 数量
• 市場シェアの分析と予測
  • タイプ別
  • 製品別
  • 適応症別
  • エンドユーザー別
  • 地域別
  • 市場シェア分析：企業別（金額）（上位5社とその他 - 2024年度）
• 市場マップ分析（2024年度）
  • タイプ別
  • 製品別
  • 適応症別
  • エンドユーザー別
  • 地域別

第5章 需給分析

第6章 輸入と輸出の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

• 市場促進要因
• 市場の課題

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

• 臨床試験
• 規制当局の承認

第14章 特許情勢

第15章 ケーススタディ

第16章 競合情勢

• マーケットリーダー上位5社の競合マトリクス
• 上位5社のSWOT分析
• 主要市場企業の主要企業の情勢
  • Biocon Limited
  • Pfizer Inc.
  • Gennova Biopharmaceuticals Ltd.
  • Biogen Inc.
  • Sarepta Therapeutics, Inc.
  • NS Pharma, Inc.
  • Novartis India Ltd.

第17章 戦略的推奨

第18章 当社について、免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. India RNA Therapeutics Market, By Value, In USD Million, FY2018-FY2032F
• Figure 2. India RNA Therapeutics Market, By Volume, In Thousand Doses, FY2018-FY2032F
• Figure 3. India RNA Therapeutics Market Share (%), By Type, FY2018-FY2032F
• Figure 4. India RNA Therapeutics Market Share (%), By Product, FY2018-FY2032F
• Figure 5. India RNA Therapeutics Market Share (%), By Indication, FY2018-FY2032F
• Figure 6. India RNA Therapeutics Market Share (%), By End-user, FY2018-FY2032F
• Figure 7. India RNA Therapeutics Market Share (%), By Region, FY2018-FY2032F
• Figure 8. By Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 9. By Product Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 10. By Indication Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
• Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024

India RNA therapeutics market is projected to witness a CAGR of 15.33% during the forecast period FY2025-FY2032, growing from USD 627.39 million in FY2024 to USD 1,909.94 million in FY2032. The market's growth is supported by the increasing prevalence of chronic diseases, rising investments towards the upgradation of healthcare and pharmaceutical sectors, growing research, and increasing support from the government.

The growing threat of different chronic diseases, including diabetes and cardiovascular diseases, is propelling the adoption of cutting-edge therapies, boosting the RNA therapeutics market demand in India. According to the estimates of the Indian Heart Association (IHA), India accounts for approximately 60% cases of heart diseases across the world. Due to the functionally specific and biologically diverse nature of RNAs, they can be used for loss- or gain-of-function purposes. Emergent technologies based on gene editing and microRNAs are reducing the burden of complex diseases in a novel manner; RNA-based gene editing is expected to provide control of complex diseases over longer periods of time and a permanent cure for monogenic cardiovascular diseases.

Unlike biological products that require bioreactors and complex setups, RNA therapies can be synthesized chemically, ensuring that it is swiftly tested and produced if a viable RNA candidate is identified. Due to the easily reproducible nature of these therapies, various market players and research organizations in the country are actively investing in identifying appropriate therapeutic solutions to combat previously undruggable diseases. Moreover, the focus on research activities on RNA therapies is also increasing in India as they can benefit large patient populations, making them essential for densely populated countries such as India.

Increasing Cases of Infectious Diseases Support Market Expansion

The rising cases of infectious diseases in the country are boosting India's RNA therapeutics market growth. As per the Department of Biotechnology estimates, infectious diseases are one of India's top ten causes of death. To combat the threat of chronic diseases in the country, various organizations are working towards the development and availability of effective therapeutic solutions. The growing knowledge about RNA and its involvement in different diseases encourages the utilization of RNAs to function on hitherto genes, transcripts, and proteins selectively. RNA therapeutics can aid in reducing the rate of infections in the country, which in turn will reduce the number of preventable deaths in India.

Growing Government Support Boosts Market Expansion

The government is promoting collaborations and partnerships between leading pharmaceutical and biotechnology companies and international players to propel the development and availability of RNA-based therapeutic solutions in the country. Additionally, the Indian regulatory framework is evolving to accommodate and facilitate the approval of RNA therapeutics, which is essential for providing innovative treatments and advancing clinical applications. Furthermore, the Indian government is also actively investing in the biotechnology sector. As per the estimates of Invest India, the country invested USD 1 billion in research and development activities in biotechnology in 2022. In order to meet the growing domestic and international demand, the country is also increasingly investing in enhancing research infrastructure and constructing bio-incubation centers. Such efforts and investments are expected to bolster the growth of the biotechnology sector and positively influence the market's expansion.

mRNA Therapeutics Account for Significant Market Share

The rising cases of various chronic diseases in the country, including cancer, are propelling the requirement for mRNA therapeutics. As per the statistical analysis of incidence rates of cancer published in the Indian Journal of Public Health, the country's cancer burden is expected to rise by 31.4% between 2015 and 2025. mRNA vaccines showcase great potential as compared to traditional cancer vaccines that are based on peptides or proteins. mRNA vaccines reconcile the requirement for commercialization and personalization that is unique to every protein and is not beholden to their human leukocyte antigen (HLA) haplotype. Another advantage of mRNA vaccines includes the availability of engineering strategies for enabling the induction of adaptive and innate immune responses. Additionally, direct injection of mRNA vaccines provides flexibility and safety in terms of speed with which antigens or personalized epitopes can be produced in mRNA form. In the future, mRNA vaccines are expected to include the optimization of nanoparticles for delivering mRNA itself as well as the vaccine.

Vaccines Hold Significant Market Share

The expansion of the segment is supported by the significantly lower production time of RNA vaccines. mRNA, responsible for encoding one or more antigens of the infectious agent, is derived from a DNA template, which can be synthesized with the help of a digital sequence and sent across the world in an instant. The production process for RNA vaccines can be easily standardized and scaled, enabling replacement of the sequence encoding the protein necessary for a new vaccine, while ensuring minimal changes to the vaccine production process. Such advantages, coupled with the increasing approval from the Government of India, are bolstering the market's expansion. In June 2023, India's first mRNA-based vaccine received approval from the Drug Control General of India (DCGI). Such approvals are expected to augment the market's demand and aid the pharmaceutical sector in meeting the evolving requirements of the patients and the healthcare sector.

Future Market Scenario (FY2025-FY2032F)

As per the India RNA therapeutics market analysis, the rapid expansion of the population, along with rising cases of chronic diseases and evolving healthcare requirements of the patients, is expected to provide lucrative growth opportunities to the market. According to the statistical analysis on incidence rates of cancer published in the Indian Journal of Public Health in 2023, the burden of cancer is estimated to rise to 2.98 million in India by 2025 from 2.67 million in 2021. As healthcare is becoming more personalized in treatment modes, the demand for RNA therapies is expected to increase in the coming years for treating chronic diseases such as cancer. Government support for research activities in RNA vaccines is expected to bolster the commercialization of these vaccines.

Collaborations between Indian companies and international players are expected to enhance the efficacy of RNA-based therapies and widen the scope of application against more diseases. Furthermore, the pharmaceutical industry in India is expected to invest heavily in expanding its manufacturing capabilities to accommodate RNA drugs and vaccines. Additionally, due to the government's emphasis on making India a global hub for biotechnology, new biomanufacturing facilities and innovation centers are being set up, which in turn are expected to support the market's growth. These facilities will aid in the local manufacturing of RNA therapies, ensuring their easy

availability.

Key Players Landscape and Outlook

The rising efforts of the key market players to propel the development of effective therapeutic solutions with the support of government organizations is expected to boost the India RNA therapeutics market size. In June 2023, the Department of Biotechnology announced that the office of the DCGI has given approval to the Omicron-specific mRNA-based booster vaccine that was supported by the Biotechnology Industry Research Assistance Council's (BIRAC) Mission COVID Suraksha and developed by Gennova Biopharmaceuticals Ltd. The vaccine was developed with the help of Gennova's indigenous platform technology. Such developments and alliances are expected to bolster the availability of essential therapeutic solutions and provide lucrative growth opportunities to the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India RNA Therapeutics Market Outlook, FY2018-FY2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. RNA Interference (RNAi) Therapeutics
    • 4.2.1.2. mRNA Therapeutics
    • 4.2.1.3. Antisense Oligonucleotide (ASO)Therapeutics
    • 4.2.1.4. Others
  • 4.2.2. By Product
    • 4.2.2.1. Vaccines
    • 4.2.2.2. Drugs
  • 4.2.3. By Indication
    • 4.2.3.1. Rare Genetic Diseases/Hereditary Diseases
    • 4.2.3.2. Infectious Diseases
    • 4.2.3.3. Others
  • 4.2.4. By End-user
    • 4.2.4.1. Hospitals
    • 4.2.4.2. Academic Research Centers
    • 4.2.4.3. Contract Research Organizations
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North
    • 4.2.5.2. East
    • 4.2.5.3. West and Central
    • 4.2.5.4. South
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
• 4.3. Market Map Analysis, FY2024
  • 4.3.1. By Type
  • 4.3.2. By Product
  • 4.3.3. By Indication
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

• 11.1. Market Drivers
• 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

• 13.1. Clinical Trials
• 13.2. Regulatory Approvals

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

• 16.1. Competition Matrix of Top 5 Market Leaders
• 16.2. SWOT Analysis for Top 5 Players
• 16.3. Key Players Landscape for Top Market Players
  • 16.3.1. Biocon Limited
    • 16.3.1.1. Company Details
    • 16.3.1.2. Key Management Personnel
    • 16.3.1.3. Products and Services
    • 16.3.1.4. Financials (As Reported)
    • 16.3.1.5. Key Market Focus and Geographical Presence
    • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 16.3.2. Pfizer Inc.
  • 16.3.3. Gennova Biopharmaceuticals Ltd.
  • 16.3.4. Biogen Inc.
  • 16.3.5. Sarepta Therapeutics, Inc.
  • 16.3.6. NS Pharma, Inc.
  • 16.3.7. Novartis India Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer